title: Location of Xpert® MTB/RIF in centralised laboratories in South Africa undermines potential impact.
authors.forename: Stephen D
authors.initials: SD
authors.lastname: Lawn
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Kerkhoff
authors.forename: Robin
authors.initials: R
authors.lastname: Wood
mesh_terms: D000995:Antitubercular Agents / Q000494:pharmacology*; D006801:Humans; D021141:Nucleic Acid Amplification Techniques / Q000379:methods*; D012293:Rifampin / Q000494:pharmacology*; D014376:Tuberculosis / Q000175:diagnosis*
chemical_list: D000995:Antitubercular Agents; D012293:Rifampin